The downgrade from Outperform to Neutral by Baird analyst Jeff Johnson indicates a less optimistic outlook for Insulet. The lowered price target from $320 to $219 also suggests that the analyst believes the stock is overvalued at its current price. This could potentially lead to a decrease in the stock's price in the short term.